Physician profile
Thomas M Irwin
NPI 1629172358
$899.90
in general payments reported to CMS, 2019-2025
14 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $91.01 · 2021: $120 · 2022: $165 · 2023: $49.19 · 2024: $241 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $279.49 | 2022-2024 | |
| Intersect Ent, INC. | $150.17 | 2019-2021 | |
| Glaxosmithkline, LLC. | $103.54 | 2021-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $95.10 | 2023-2025 | Dupixent |
| Stryker Corporation | $71.32 | 2019 | |
| Phadia US INC. | $38.62 | 2021-2024 | Immunocap |
| Olympus America INC. | $27.84 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $26.55 | 2025 | Neffy |
| Optinose US, INC. | $25.23 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $20.18 | 2025 | Voquezna |
| Uswm, LLC | $19.00 | 2021 | |
| Pharming Healthcare, INC. | $16.71 | 2024 | Ruconest |
| Merck Sharp & Dohme LLC | $14.72 | 2023 | |
| Cook Medical LLC | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Irwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.